Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 4;2(1):301.
doi: 10.1186/2193-1801-2-301. Print 2013 Dec.

What makes cancer stem cell markers different?

Uwe Karsten  1 , Steffen Goletz
Affiliations

What makes cancer stem cell markers different?

Uwe Karsten et al. Springerplus. .

Abstract

Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers? A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers. Glycosylation may provide the key.

Keywords: Cancer stem cells; Glycosylation; Stem cells; Therapeutic targets; Thomsen-Friedenreich antigen.

PubMed Disclaimer

References

    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–3988. doi: 10.1073/pnas.0530291100. - DOI - PMC - PubMed
    1. Annaloro C, Onida F, Saporiti G, Lambertenghi Deliliers G. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. Curr Pharm Biotechnol. 2011;12:217–225. doi: 10.2174/138920111794295747. - DOI - PubMed
    1. Augello A, Kurth TB, De Bari C. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur Cells Mat. 2010;20:121–133. - PubMed
    1. Baba M, Ma BY, Nonaka M, Matsuishi Y, Hirano M, Nakamura N, Kawasaki N, Kawasaki N, Kawasaki T. Glycosylation-dependent interaction of Jacalin with CD45 induces T lymphocyte activation and Th1/Th2 cytokine secretion. J Leukoc Biol. 2007;81:1002–1011. doi: 10.1189/jlb.1106660. - DOI - PubMed
    1. Badcock G, Pigott C, Goepel J, Andrews PW. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratin sulfate proteoglycan. Cancer Res. 1999;59:4715–4719. - PubMed